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introduction
INTRODUCTION 
Ischemic heart disease (IHD) is a leading cause of death in the 
western world  and increased incidence  in our country also. Most of the 
subjects with IHD have one or more traditional risk factors including 
diabetes, smoking history, hypertension, obesity, a family history of IHD 
and  hyperlipidimia1.  In recent years new risk factors for IHD have been 
identified, including the presence of  inflammation as demonstrated by 
raised highly sensitive C-reactive protein (hs-CRP)2. Subjects with 
chronic inflammatory diseases such as rheumatoid arthritis (RA)  and 
systemic lupus   erythematosus also have  a greatly increased risk of 
developing IHD3. 
The autoantibody rheumatoid factor (RF) is strongly  associated 
with  RA, may be  present in subjects many years  before they develop 
RA4 and its presence confers a risk of developing RA that increases with 
increasing titre5. However  RF is associated  with other  autoimmune  
rheumatic disease, viral  or bacterial infections and  is present  in as many 
as 15% of normal adults. 6Recently, RF has been associated with an 
increased likelihood of developing IHD in patients with inflammatory  
polyarthritis. 
Presence of  RF in general population may identify the subjects 
with a similar immune pathology to patients  with RA ,who may also 
share an increased likelihood of developing IHD and that RF may have 
special role in  the pathogenesis of IHD. 
To explore this, the study was  conducted to find out whether  the 
presence of  RF was  associated  with  increased risk of  IHD  among  
general population.  
                
 
 
 
 
 
 
 
 
  
 
Aim of the study
 AIMS AND OBJECTIVES 
 
1. To analyse  the   RF as an independent  and additional risk factor  
for IHD in general population. 
2.     To compare the association of RF as a risk factor in male and 
female population with relevance to high and low titres. 
                                                   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Review of 
literature
REVIEW OF LITERATURE 
The coronary  circulation  is  unique  in that it is responsible  for 
generating the arterial pressure that is required to perfuse the systemic 
circulation and yet at the same time has its own  perfusion impeded 
during the systolic portion  of the cardiac cycle. Because myocardial 
contraction  is closely connected to coronary flow and oxygen  delivery,  
the balance between oxygen supply and demand is a critical determinant 
of the normal beat to beat function  of the heart. When this relationship is 
acutely disturbed by disease affecting coronary blood flow, the resulting  
imbalance can immediately precipitate a vicious cycle, where by 
ischemia-induced contractile dysfunction  precipitates hypotension  and 
further  myocardial ischemia. IHD causes more deaths and disability and 
incurs greater economic costs than any other illness in the developed 
world. 
IHD is the most common, serious, chronic, life-threatening illness 
in the world wide.  A high fat and energy-rich diet, smoking, and a 
sedentary lifestyle are associated with the emergence of IHD.  In the 
United States and Western Europe, it is growing among low-income 
groups rather than high-income groups (who are adopting more healthful 
lifestyles), while primary prevention has delayed the disease to later in 
life in all socioeconomic groups. 
Obesity, insulin resistance, and type 2 diabetes mellitus are 
increasing and are powerful risk factors for IHD. With urbanization in the 
developing world, the prevalence of risk factors for IHD is increasing 
rapidly in these regions such that a majority of the global burden of IHD 
is now occurring in low-income and middle-income countries. Population 
subgroups that appear to be particularly affected are men in South Asian 
countries, especially India. Given the projection of large increase  in IHD 
throughout the world, IHD is likely to become the most common cause of 
death worldwide by 2020. 
Central to an understanding of the pathophysiology of myocardial 
ischemia is the concept of myocardial supply and demand. Under normal 
conditions, for any given level of a demand for oxygen, the myocardium 
will be supplied with oxygen-rich blood to prevent underperfusion of 
myocytes and the subsequent development of ischemia and infarction.  
The major determinants of myocardial oxygen demand are heart 
rate, myocardial contractility,  and  myocardial wall tension (stress).  An 
adequate  supply of  oxygen to the  myocardium  requires  a satisfactory  
level of  oxygen-carrying  capacity of  the  blood (determined by the 
inspired level of oxygen, pulmonary function, and hemoglobin 
concentration and function)  and an adequate level of coronary blood 
flow. Blood flows through the coronary arteries in a phasic fashion, with 
the majority occurring during diastole. About 75% of the total coronary 
resistance to flow occurs across three sets of arteries: 
    (1) large epicardial arteries  
(2) prearteriolar vessels  
           (3) arteriolar and intramyocardial capillary vessels.  
In the absence of significant flow-limiting atherosclerotic 
Obstruction, the normal coronary circulation is dominated and controlled 
by the heart's requirements of oxygen. This need is met by the ability of 
the coronary vascular bed to vary its resistance (and, therefore, blood 
flow) considerably while the myocardium extracts a high and relatively 
fixed percentage of oxygen. Normally, intramyocardial resistance vessels 
demonstrate an immense capacity for dilation. For example, the changing 
oxygen needs of the heart with exercise and emotional stress affect 
coronary vascular resistance and in this manner regulate the supply of 
oxygen and substrate to the myocardium (metabolic regulation). The 
coronary resistance vessels also adapt to physiologic alterations in blood 
pressure in order to maintain coronary blood flow at levels appropriate to 
myocardial needs (autoregulation). 
By reducing the lumen of the coronary arteries, atherosclerosis 
limits appropriate increases in perfusion when the demand for flow is 
augmented, as occurs during exertion or excitement. When the luminal 
reduction is severe, myocardial perfusion in the basal state is reduced. 
Coronary blood flow can also be limited by spasm, arterial thrombi, and, 
rarely, coronary emboli as well as by ostial narrowing due to aortitis. 
Congenital abnormalities, such as origin of the left anterior descending 
coronary artery from the pulmonary artery, may cause myocardial 
ischemia and infarction in infancy, but this cause is very rare in adults. 
Myocardial ischemia can also occur if myocardial oxygen demands 
are markedly increased and when coronary blood flow may be limited, as 
occurs in severe left ventricular hypertrophy due to aortic stenosis. The 
latter can present with angina that is indistinguishable from that caused 
by coronary atherosclerosis largely owing to subendocardial ischemia. A 
reduction in the oxygen-carrying capacity of the blood, as in extremely 
severe anemia or in the presence of carboxyhemoglobin, rarely causes 
myocardial  ischemia by itself but may lower the threshold for ischemia 
in patients with  moderate coronary obstruction. 
Not infrequently, two or more causes of ischemia coexist, such as 
an increase in oxygen demand due to LV hypertrophy secondary to  
hypertension and a reduction in oxygen supply secondary to coronary 
atherosclerosis and anemia. Abnormal constriction or failure of normal 
dilation of the coronary resistance vessels can also cause ischemia. When 
it causes angina, this condition is referred to as microvascular angina. 
From a practical viewpoint, the cardiovascular risk factors that 
have emerged from such studies fall into two categories: those modifiable 
by lifestyle and/or pharmacotherapy and those that are essentially  
unmodifiable. The weight of evidence supporting various risk factors 
differs. For example, hypercholesterolemia and hypertension certainly 
predict coronary risk, but other so-called nontraditional risk factors, such 
as levels of homocysteine, lipoprotein (a)  or infection, remain 
controversial. One must further distinguish factors that actually 
participate in atherogenesis from those that may merely serve as markers 
of risk without direct involvement in pathogenesis. The following Lists 
the risk factors recognized by the current National Cholesterol Education 
Project  Adult Treatment Panel- III. The sections below will consider 
some of  these risk factors and approaches to their modification. 
 
 Cigarette smoking  
 Hypertension (BP ≥ 140/90 mmHg or on 
antihypertensive medication) 
 Low HDL cholesterol[<1.0 mmol/L (<40 mg/dL)]  
 Diabetes mellitus 
 Family history of premature CHD 
o CHD in male first-degree relative <55 
years  
o CHD in female first-degree relative <65 
years  
• Age (men ≥45 years; women ≥55 years 
• Lifestyle risk factors  
o Obesity   
o Physical inactivity  
o Atherogenic diet  
• Emerging risk factors  
o Lipoprotein(a)  
o Homocysteine  
o Prothrombotic factors 
o Proinflammatory factors  
o Impaired fasting glucose  
o Subclinical atherogenesis 
 
Ischemic heart disease is most often due to atherosclerotic  
coronary  artery  disease. The importance  of  inflammation  in 
atherosclerosis  is  also  supported  by  the  finding of   inflammatory  
cells  in atherosclerotic  lesions . The  following  conditions  are  
associated  with inflammatory/ proinflammatory  factors- identified as 
probable causative factors for IHD. 
1) Rheumatoid arthritis 
2) Systemic lupus erthymatosus 
3) Antiphospholipid  antibody syndrome 
4) Vassculitis producing other connective tissue disorders 
Of these inflammatory/ proinflammatory factor,  RF  is  one of the  
independent and additional risk factor for IHD.   
 
ROLE  OF  RHEUMATOID FACTOR  IN  IHD: 
The association  of  RF with IHD  provides evidence of  an  
importance of inflammation and raises the possibility that  autoimmune  
mechanisms  may play  a part.   The   present study  cannot determine  
whether  RF   is a  non-specific marker of inflammation or is involved  
directly  in   pathogenesis   of atherosclerosis in the subjects included.   
However , RF appears  to cause direct tissue damage  in  RA  as a 
constituent of immune  complexes13, perhaps by activating complement.  
It might  cause  damage  to  the  vascular  endothelium  in the same  way.  
There  is circumstantial  evidence for this: Atherosclerotic  plaques  
contain  immunoglobulins and complements suggesting immune complex  
activity15. In addition  the  lack of    relationship  between  IHD and  the  
autoantibodies  ANA  and ACA  suggests  that  the association  between 
RF  and  IHD  may not be   due to  non-specific polyclonal  B-cell 
activation secondary to inflammation, but the unique role of  RF in  the  
pathogenesis  of atherosclerosis/IHD.  
This is further  supported  by  the association of  RF  with  IHD  in  
subjects   with  inflammatory arthritis7. There  is  also  an  intriguing  
possibility that  the  pathological  process  involved  in  IHD  such as  
atheroma  formation,  may  generate  inflammatory  tissue capable of 
producing  RF.  Infections  cause  inflammation  and  can  induce  RF  
production, although  this is  usually  short  lived. Chronic  infections  
that  induce  persistent RF  is  rare. Acute  infections  are associated  with  
an increased  risk  of  cardiovascular  events, perhaps  by inducing  
circulating  cytokines  or an  autoimmune  response16.  
 
RHEUMATOID ARTHRITIS  (RA): 
RHEUMATOID ARTHRITIS  is a chronic multisystem disease of 
unknown cause. Although there  are a variety of systemic manifestations, 
the characteristic feature of established RA is persistent inflammatory 
synovitis, usually involving peripheral joints in a symmetric distribution. 
The prevalence of rheumatoid arthritis (RA) is ~ 0.8% of the 
population. Women are affected approximately three times more often 
than men. The prevalence increases with age, and sex differences 
diminish in the older age group. RA is seen throughout the world and 
affects all races. The onset is more frequent during the fourth and fifth 
decades of life, with 80% of all developing the disease between the ages 
of 35 and 50.  
The cause of RA remains unknown. The class II major 
histocompatibility complex allele HLA-DR4 and related alleles are 
known to be major genetic risk factors for rheumatoid arthritis(RA). 
Genetic risk factors do not fully account for the incidence of RA. The 
environmental factors also play a role in the etiology of the disease. It has 
been suggested that RA might be a manifestation of the response to an 
infectious agent in a genetically susceptible host. 
Microvascular injury and an increase in the number of synovial 
lining cells appear to be the earliest lesions in rheumatoid synovitis. 
Before the onset of clinical symptoms, the perivascular infiltrate is 
predominantly composed of myeloid cells, whereas in symptomatic 
arthritis, T cells can also be found, although their number doesnot 
correlate with symptoms. 
Light-microscopic examination discloses a characteristic 
constellation of features, which include hyperplasia and hypetrophy of the 
synovial lining cells; focal or segmental vascular changes, including 
microvascular inury, thrombosis and neovascularization; edema; and 
infiltration with mononuclear cells, often collected into aggregates around 
small blood vessels. The rheumatoid synovium is characterized by the 
presence of a number of secreted products of activated lymphocytes, 
macrophages and fibroblasts. The propagation of RA is an 
immunologically mediated event. The inflammatory process in the tissue 
is driven by the CD4+ T cells infiltrating the synovium. 
The systemic manifestations of RA can be accounted for by release 
of inflammatory effector molecules from the synovium. These include IL-
1, TNF, and IL-6, which account for many of the manifestations of active 
RA, including malaise, fatigue, and elevated levels of serum acute-phase 
reactants. The importance of TNF in producing these manifestations is 
emphasized by the prompt amelioration of symptoms following 
administration of a monoclonal antibody to TNF or a soluble TNF 
receptor Ig construct to patients with RA. In addition, immune complexes 
produced within the synovium and entering the circulation may account 
for other features of the disease, such as systemic vasculitis. 
Characteristically, RA is a chronic polyarthritis. Specific symptoms 
usually appear gradually as several joints, especially those of the hands, 
wrists, knees, and feet, become affected in a symmetric fashion. 
RA is a systemic disease with a variety of extraarticular 
manifestations. It is estimated that as many as 40% of patients may have 
extraarticular manifestations, and in ~15% these are severe. On occasion, 
extraarticular manifestations may be the major evidence of disease 
activity and source of morbidity. As a rule, these manifestations occur in 
individuals with high titres of autoantibodies to the Fc component of 
immunoglobulin G (rheumatoid factor) or with antibodies to CCP. 
Although the frequency of patients with severe extra articular 
manifestations appears to be declining, these patients have an increased 
mortality compared to other persons with rheumatoid arthritis or age- 
matched normal controls. 
       Rheumatoid vasculitis , which can affect nearly any organ system, 
is seen in patients with svere RA and high titres of circulating rheumatoid 
factor. Rheumatoid vasculitis in its most aggressive form, can cause 
polyneuropathy and mononeuritis multiplex, cutaneous ulceration and 
dermal necrosis, digital gangrene, and visceral infarction. While such 
widespread vasculitis is very rare, more limited forms are not uncommon, 
especially in patients with high titres of rheumatoid factor. Neurovascular 
disease presenting either as a mild distal sensory neuropathy or as 
mononeuritis multiplex may be the only sign of vasculitis. Cutaneous 
vasculitis usually presents as crops of small brown spots in the nail beds, 
nail folds, and digital pulp. Larger ischemic ulcers, especially in the lower 
extremity, may also develop. Myocardial infarction secondary to 
rheumatoid vasculitis has been reported as has vasculitic involvement of 
lungs, bowel, liver, spleen, pancreas, lymph nodes, and testes. 
       Evidence of asymptomatic pericarditis is found at autopsy in 50% 
of cases. Pericardial fluid has a low glucose level and is frequently 
associated with the occurance of pleural effusion. Although pericarditis is 
usually asymptomatic, on rare occasions death has occurred from 
tamponade. Chronic constrictive pericarditis may also occur. More 
recently, an increased incidence of congestive heart failure and death 
from cardiovascular disease has been associated with RA.       
 
THE 1987 REVISED CRITERIA FOR THE CLASSIFICATION  
OF RHEUMATOID ARTHRITIS : 
These criteria demonstrate a sensitivity of 91-94% and a specificity 
of 89% when used to classify patients with RA compared with control 
subjects. Failure to meet these criteria, however, especially during the 
early stages of the disease, does not exclude the diagnosis.  
 
1.GUIDELINES FOR CLASSIFICATION 
a.  Four of seven criteria are required to classify a patient as having 
rheumatoid arthritis (RA) 
b.  Patients with two or more clinical diagnoses are not excluded. 
 
 
 
 
 
2.CRITERIA* 
a. Morning stiffness: stiffness in and around joint lasting 1 h before 
maximal improvement.  
b.  Arthritis of three or more joint area: the 14 possible joint areas 
involved are right or left proximal interphalangeal, 
metacarpophalangeal, wrist, elbow, knee, ankle, and 
metatarsophalangeal joints. 
c.  Arthritis of hand joints: arthritis of wrist, metacarpophalangeal or 
proximal interpahalangeal joint. 
d.  Symmetric arthritis: simultaneous involvement of the same joint 
areas on both sides of the body. 
e.  Rheumatoid nodules: subcutaneous nodules over bony 
prominences, extensor surfaces, or juxtaarticular regions observed by 
a physician. 
f.  Serum rheumatoid factor: demonstration of abnormal amounts of 
serum rheumatoid factor by any method for which the result has 
been positive in less than 5% of normal control subjects. 
g.  Radiographic changes: typical changes of RA on posteroanterior 
hand and wrist radiographs that must include erosions or 
unequivocal bony decalcification localized in or most marked 
adjacent to the involved joints. 
*criteria a-d must be present for atleast 6 weeks. 
*criteria b-e must be observed by a physician. 
      
 Patients  with  rheumatoid arthritis have  an  increased prevalence  
of  IHD. This is most likely in those  people  with  the  autoantibody RF, 
which are strongly   associated   with  RA  but is also  present in up to 
15% of all adults.  Atherosclerotic plaque is a complex inflammatory 
lesion characterized by  an   infiltrate of macrophages and T cells1. Intra 
plaque immune cells are activated and   involved in mediating tissue 
injury5. T-cell cytokines can drive macrophage activation in 
atherosclerotic lesions and can also regulate the acute-phase response1. 
Indeed, T cells in patients with acute coronary syndromes (ACS) are 
skewed toward  the production of interferon (IFN)-γ, a potent  monocyte 
activator largely derived  from a distinct subset of CD4+ T cells6,7  that, in 
contrast to classic CD4+ helper T cells, lacks the  co-stimulatory 
molecule CD288. CD4+CD28null T cells are clonally expanded in ACS 
and invade the unstable  atherosclerotic  plaque9.                                
Moreover, CD4+CD28null T cells have cytotoxic  capability, can 
effectively kill  Endothelial cells in vitro, and  may contribute to 
endothelial cell injury in coronary plaque10. Expansion of CD4+CD28null 
T cells was initially described in patients  with  rheumatoid arthritis (RA), 
a chronic autoimmune  disease of unknown etiology11.  RA is 
characterized by chronic inflammation and hyperplasia of synovial tissue.  
More  importantly, it is a quintessential systemic disease that can 
manifest in most major organ systems12.                                               
T cells play a central  role in the Immune pathogenesis of RA and 
are the key regulators of the chronic destructive joint lesions13. In 
addition, patients with RA have abnormalities in T-cell homeostasis that  
affect the entire pool of T cells14,15. One of the consequences of 
dysregulated T-cell homeostasis is the emergence  of large  clonal 
CD4+CD28  null T-cell populations that are auto reactive  and cytotoxic, 
and infiltrate synovial tissue15. The highest frequency of CD4+CD28null 
T cells is found in severe RA,  particularly in  patients with rheumatoid 
vasculitis11,16.   
When the inflammatory   process in   RA spreads to extra-articular 
sites,  such as mid-size  arteries  and capillaries,  morbidity  and mortality 
are clearly increased17. The inflammatory mechanisms in RA may 
enhance atherogenesis in several ways. C-reactive protein, a useful 
marker of disease  activity, is elevated in RA and has prognostic value.  It 
may also participate directly in endothelial injury by sensitizing 
endothelial cells to T-cell mediated cytotoxicity.                                                 
Circulating   cytokines in RA, such as TNF-α, result in endothelial  
activation and up-regulation of adhesion molecules. Indeed, endothelial 
dysfunction is frequently present in RA patients, even in the absence of 
identifiable Cardiovascular risk factors  and  improves with anti-TNF-α 
therapy . Cytokines will  also non-specifically activate monocytes and 
other cells of the   innate immune system. RA is characterized by the 
expansion of auto reactive T-cell clones that typically lack CD28. The  
frequency of such CD4+CD28 null T cells correlates with disease   
severity with respect to erosive progression  and   extra-articular 
manifestations. The frequency in the RA with CAD cohort (median 3.5%) 
was higher than in historical controls of patients with RA and absence of 
extra-articular manifestations, suggesting that CV co-morbidity in RA is  
correlated with disease severity and that CD4+CD28null T cells  may be 
involved in the Cardio Vascular complications of RA. CD4+CD28nullT 
cells have been directly implicated in the pathogenesis of coronary artery 
disease. Persistent activation of such auto reactive cells in RA may result 
in a vicious cycle of cytokine  release, mononuclear cell activation and 
tissue injury.                                                                                                                      
However, we cannot exclude the possibility that  the high  
CD4+CD28null T cells  levels in RA with CAD patients is reflective   of 
an increased RA disease severity  in these patients.  Addressing this issue 
further will require comparing RA  patients that are matched for disease 
severity. 
The impact of severe RA on mortality may  be mediated via 
reduced physical activity that will compromise cardio respiratory fitness. 
This might contribute to higher Cardio vascular  mortality in RF-positive 
RA patients. Disability has been shown to be a predictor of all-cause and 
Cardiovascular mortality in early inflammatory polyarthritis and 
established RA.  
More severe RA is also associated with a  higher cumulative 
inflammatory disease burden. Atherosclerosis is now accepted to be an 
inflammatory condition, and elevation of inflammatory markers including 
high-sensitivity C-reactive protein (CRP) has been associated with the 
subsequent development of Cardio vascular events in the general 
population, and histological study has identified the presence of 
inflammatory cells in atherosclerotic plaque in the general population. If 
atherosclerosis is promoted by chronic low-grade  inflammation, as 
suggested by Ridker, it is plausible that atherosclerosis may be 
accelerated in chronic systemic inflammatory conditions like RA15. A 
previous study of the Rochester RA cohort demonstrated that cumulative 
inflammation measured using the erythrocyte sedimentation rate (ESR) 
was associated with subsequent Cardio vascular events. In addition, 
modest elevations in baseline CRP were associated with subsequent 
Cardio vascular mortality in patients with early inflammatory 
polyarthritis who were registered with the Norfolk Arthritis Register.  
Effective drug therapy, which reduces inflammation in RA, has 
been shown to reduce all-cause and CVD mortality, and responders to 
anti-tumor necrosis factor-a therapies were found to have a lower 
incidence of myocardial infarction than  non-responders. Therefore RF-
positive patients may have increased ischemic heart  disease mortality 
because they have increased levels of chronic inflammation, and 
suppression of this inflammation may lead to improved survival.  
Other factors associated with RF status and  severity of RA include 
anti-CCP status and presence of the HLA-DRB1 shared  epitope. High 
titers of anti-CCP predicted mortality in a study of RA patients in 
Finland. A recent study reported that, while RF status and anti-CCP status 
were each associated with mortality in inflammatory polyarthritis, 
possession of both markers did not confer a higher mortality risk. In 
addition there was a significant interaction between these 3 variables in 
the models predicting mortality. Therefore mortality outcome in 
inflammatory arthritis appears to be associated with variables that 
promote more severe disease.  
It has been hypothesized that circulating immune complexes and 
RF might have a direct effect on endothelial cells to promote 
atherosclerosis. Dessein, et al reported that RF and interleukin 6 were 
associated with biomarkers of endothelial dysfunction in RA patients, 
even after adjusting for traditional CVD risk factors. Impaired nitrate-
mediated vascular dilation was found to be associated with circulating 
levels of immune complexes in RA, and this has been suggested to be one 
of the mechanisms by which atherosclerosis is promoted in RA. It is 
interesting to note that B lymphocytes have been identified in 
atherosclerotic plaques of RA patients51, while in atherosclerotic plaques 
of non-rheumatoid patients T lymphocyte infiltration is observed. 
Therefore there is some modest evidence that RF may be involved in the 
pathogenesis of atherosclerosis in RA.  
Excess mortality in RA is largely confined to those who are RF-
positive. It is still unclear whether RF itself contributes to the reduced life 
expectancy of patients with RA, or whether it is simply a marker for more 
severe disease and higher cigarette smoking exposure. Early use of 
disease modifying antirheumatic drugs and use of biologic agents to 
suppress inflammatory disease is likely to influence the life expectancy of 
these patients, and it will be interesting to explore whether cardio 
vascular disease outcomes in patients treated with B cell suppression are 
improved. However, it is likely that a combined approach is required, 
with modification of lifestyle factors, as well as suppression of the 
inflammatory disease process, to improve the mortality outcome in RF-
positive subjects.  
RA is characterized by chronic inflammation and hyperplasia of 
synovial tissue. More importantly, it is a quintessential systemic disease 
that can manifest in most major organ systems. T cells play a central role 
in the immunopathogenesis of RA and are the key regulators of the 
chronic destructive joint lesions. In addition, patients with RA have 
abnormalities in T-cell homeostasis that affect the entire pool of T cells. 
One of the consequences of dysregulated T-cell homeostasis is the 
emergence of large clonal CD4+CD28null T-cell populations that are auto 
reactive and cytotoxic, and infiltrate synovial tissue. The highest 
frequency of CD4+CD28null T cells is found in severe RA, particularly in 
patients with rheumatoid vasculitis. When the inflammatory process in 
RA spreads to extra-articular sites, such as mid-size arteries and 
capillaries, morbidity and mortality are clearly increased. 
Because the chronic inflammatory process and immune 
dysregulation in RA have features in common with those involved in 
atherosclerosis, they could predispose patients with RA to accelerated 
CAD. Several studies have documented an increased risk of 
atherosclerosis and myocardial infarction in patients with RA18-20. In 
addition, RA is associated with a reduced life expectancy, primarily 
because of excessive deaths from cardio vascular disease21-25. RA is a 
heterogeneous disease, and the disease phenotype itself is predictive of 
mortality; patients with more severe clinical disease have higher mortality 
rates26. Overall mortality is also increased in patients who are positive for 
the autoantibodies, rheumatoid factors27,28. In addition, the extent of 
inflammation in RA has been linked to an increased risk of cardio 
vascular mortality29. The number of swollen joints, independent of 
traditional cardio vascular risk factors, is predictive of cardio vascular 
related deaths among Pima Indians with RA30. The strongest association 
with increased cardio vascular mortality is seen in patients with extra-
articular manifestations of RA17.                    
         Inflammation is part of the process of atherosclerotic disease, and 
patients with inflammatory diseases, such as rheumatoid arthritis and 
systemic  lupus  erthymatosus, are at increased risk for cardiovascular 
events. Among patients with rheumatoid arthritis, testing positive for 
circulating rheumatoid factor (RF) represents an added risk for ischemic 
heart disease.RF may be present in 15% of the general population without 
clinical rheumatoid arthritis. This factor may be acquired through the 
presence of other autoimmune disease or previous bacterial infections. In 
addition, it appears that smokers have higher rates of testing positive for 
RF. The current study examines whether RF represents an independent 
risk factor for ischemic heart disease in a general population of patients.  
In the general population, the presence of advanced  atherosclerosis 
on angiography is predictive of a worse prognosis. The extent of 
atherosclerosis determined by angiography has not been studied in RA. 
Indirect evidence of accelerated atherosclerosis in RA comes from studies 
using carotid artery intima medial thickness as a marker of atherosclerotic 
burden and vascular risk. Increased intima-media thickness was 
independent of traditional Cardio vascular  risk factors but was related to 
RA disease activity, duration and severity.Data presented here suggest 
that the acceleration of atherosclerotic disease in RA holds for multiple 
vascular beds, lending support to a systemic disease mechanism. 
Patients with RA have a significantly higher prevalence of angina 
pectoris. Also, women with RA have a significantly increased risk of 
myocardial infarction compared with those without RA. This excess of 
Cardio vascular disease in RA cannot be explained by the traditional 
Framingham risk factors and probably arises from the underlying disease 
and/or its treatment. There is no evidence that disease-modifying 
antirheumatic drug (DMARD) therapy increases mortality in RA. 
Corticosteroids can cause dyslipidemia, hyperglycemia and hypertension 
but may also control inflammation in RA. Studies have attempted to 
define the impact of steroids on mortality in RA but the results are 
inconsistent.DMARD treatment can actually improve the outcome in RA. 
Choi and colleagues have demonstrated that methotrexate-treated patients 
had a 70% reduction in CV deaths compared with those who did not 
receive disease-modifying therapy. Other DMARDs such as 
sulfasalazine, penicillamine, hydroxychloroquine, and gold did not confer 
this protection. Thus, the RA disease process itself likely contributes to 
accelerated CAD. 
The inflammatory mechanisms in RA may enhance atherogenesis 
in several ways. C-reactive protein, a useful marker of disease activity, is 
elevated in RA and has prognostic value37. It may also participate directly 
in endothelial injury by sensitizing endothelial cells to T-cell mediated 
cytotoxicity10. Circulating cytokines in RA, such as TNF-α, result in 
endothelial activation and up-regulation of adhesion molecules38. Indeed, 
endothelial dysfunction is frequently present in RA patients, even in the 
absence of identifiable CV risk factors39  and improves with anti-TNF-α 
therapy40. Cytokines will also non-specifically activate monocytes and 
other cells of the innate immune system. RA is characterized by the 
expansion of auto reactive T-cell clones that typically lack CD2811. The 
frequency of such CD4+CD28null T cells correlates with disease severity 
with respect to erosive progression41 and extra-articular manifestations. 
The frequency in the RA with CAD cohort (median 3.5%) was higher 
than in historical controls of patients with RA and absence of extra-
articular manifestations11, suggesting that CV co-morbidity in RA is 
correlated with disease severity and that CD4+CD28null T cells may be 
involved in the CV complications of RA.CD4+CD28null T cells have been 
directly implicated in the pathogenesis of coronary artery disease6. 
Persistent activation of such autoreactive cells in RA may result in a 
vicious cycle of cytokine release, mononuclear cell activation and tissue 
injury.However, we cannot exclude the possibility that the high 
CD4+CD28null T cells levels in RA with CAD patients is reflective of an 
increased RA disease severity in these patients. Addressing this issue 
further will require comparing RA patients that are matched for disease 
severity but are disparate for CAD.                    
Patients with RA have a significantly higher prevalence of  angina 
pectoris34. Also, women with RA have a significantly increased risk of 
myocardial infarction compared with those without RA18. This excess of 
cardio vascular  disease in RA cannot be  explained by the traditional 
Framingham risk factors and  probably arises from the underlying disease 
and/or its treatment. 
There is no evidence that disease-modifying antirheumatic  drug 
(DMARD) therapy increases mortality in RA. Corticosteroids can cause 
dyslipidemia, hyperglycemia and  hypertension but may also control 
inflammation in RA. Studies  have attempted to define the impact of 
steroids on mortality in  RA but the results are inconsistent. DMARD 
treatment  can actually improve the outcome in RA. Choi and 
colleagues36  have demonstrated that methotrexate-treated patients  had a 
70% reduction in CV deaths compared with those who  did not receive 
disease-modifying therapy. Other DMARDs  such as sulfasalazine, 
penicillamine, hydroxychloroquine, and  gold did not confer this 
protection. Thus, the RA disease process  itself likely contributes to 
accelerated CAD. The inflammatory mechanisms in RA may enhance 
atherogenesis  in several ways. C-reactive protein, a useful marker of 
disease  activity, is elevated in RA and has prognostic value.   It may also 
participate directly in endothelial injury by sensitizing  endothelial cells 
to T-cell mediated cytotoxicity. Circulating cytokines in RA, such as 
TNF-α, result in endothelial   activation and up-regulation of adhesion 
molecules.  Indeed, endothelial dysfunction is frequently present in RA 
patients, even in the absence of identifiable CV risk factors   and 
improves with anti-TNF-α therapy.  
Cytokines will   also non-specifically activate monocytes and other 
cells of the   innate immune system. RA is characterized by the expansion 
of autoreactive T-cell clones that typically lack CD28. The   frequency of 
such CD4+CD28null T cells correlates with disease   severity with 
respect to erosive progression  and    extra-articular  manifestations. The  
CD4+CD28null T cells have been directly implicated in the pathogenesis 
of  coronary artery disease. Persistent activation of such autoreactive    
cells in RA may result in a vicious cycle of cytokine   release, 
mononuclear cell activation and tissue injury.However,  we cannot 
exclude the possibility that the high   CD4+CD28null T cells levels in RA 
with CAD patients is reflective  of an increased RA disease severity in 
these patients. Addressing this issue further will require comparing RA 
patients that are matched for disease severity but are disparate  for  CAD. 
 
SYSTEMIC LUPUS ERTHTYMATOSUS 
  Atherosclerotic disease is common in systemic lupus erthymatosus  
and is the result of multiple pathogenic mechanisms that include 
traditional risk factors as well as SLE-related factors. Endothelial 
dysfunction and arterial stiffness contribute significantly to the  
atherogenic process.  Accelerated atherosclerosis is a significant cause of 
morbidity and mortality in systemic lupus erthymatosus. Both arteritis 
and atherosclerosis can involve the coronary arteries of young  patients 
suffering from SLE. Coronary arteritis, though rare, occurs in association 
with active vasculitis in other organs  such as skin, spleen, kidneys, etc. 
Coronary spasm  in SLE patients is rare, and  when it occurs, it is usually 
in relation to the two common  pathological processes   mentioned above. 
Systemic lupus erthymatosus is an autoimmune disorder affecting 
multiple  organ systems. Patients with systemic lupus erthymatosus 
exhibit a bimodal  pattern of mortality, with those who have had the 
disease for 5 to 10 years  being at increased risk of cardiovascular 
disease,particularly myocardial  infarction. Elevated levels of 
conventional cardiovascular risk factors  promote vascular damage 
resulting in impairment of normal endothelial  function. In addition, 
autoantibodies directed against oxidized lipoproteins, along with chronic 
secretion of inflammatory cytokines and suppression of  fibrinolytic 
parameters, are thought to increase atherogenesis. It is no longer a matter 
of dispute that SLE patients have an increased risk of developing 
atherosclerotic cardiovascular disease, particularly  before the age of 50. 
The incidence of coronary heart disease in women with SLE aged 35–44 
years has been estimated to be 50- fold greater than in the general 
population, and the cumulative   prevalence of CAD in SLE patients was 
8.9%. Early detection and management  of  atherosclerosis may reduce 
the morbidity and  improve the survival of patients with SLE. 
 Etiologies of myocardial damage in SLE patients include 
premature atherosclerotic disease, antiphospholipid antibody syndrome, 
coronary artery spasm, coronaryartery vasculitis and restenosis after 
percutaneous revascularization procedures. The following discussion will 
focus on the diagnosis and pathogenesis of coronary artery disease with 
an emphasis on premature atherosclerosis and coronary vasculitis in 
patients with SLE. 
Coronary artery vasculitis remains an infrequent complication of 
SLE. Prior to the widespread use of coronary angiography, coronary 
vasculitis was a post mortem diagnosis. Coronary angiography has helped 
in evaluating patients with suspected coronary vasculitis. It has been 
suggested that a rapid rate of progression of coronary lesions is more 
suggestive of a vasculitic process and, therefore, single angiographic 
studies may be inadequate. One case report documented a tertiary referral 
center experience where only two patients younger than  35 years of age 
with coronary vasculitis were identified over a period of 40 years.  A 
possible mechanism of arterial injury in SLE might be the development 
of auto-antibodies that may target the heart or the blood vessels.  
According to Dangas et al., there are increased auto-antibodies against 
actin and myosin during and after an acute coronary syndrome. The 
present case represents only the fourth case reported in detail with SLE 
and coronary artery disease in a patient younger than 21 years old. The 
diagnosis of coronary vasculitis secondary  to SLE in this case is 
suggested by the documentation of the diagnosis of SLE, the absence of 
classic risk factors for atherosclerotic heart disease (no evidence of 
diabetes, hypertension, family history of CAD or smoking) and the 
occurrence of angina pectoris or myocardial infarction at a young age. 
In addition to premature coronary artery disease, there was clearly 
a rapid change in the patient’s anatomy after coronary artery bypass graft 
surgery with total occlusion of 3 out of 4 grafts over only a 4-month 
period. The fourth graft displayed segmental narrowing. This is higher 
than early occlusion rates reported in multiple trials. Also, the internal 
mammary artery of our patient displayed areas of fibrosis and intimal 
thickening per the operative report, precluding its use as a graft. These 
events suggest vasculitis as a possible etiology for her deterioration, as is 
suggested from the pathology slide. Immune complex deposition in the 
coronary artery walls in patients with SLE  have been documented via 
immunofluorescence studies and the relationship between inflammatory 
immunologic injury and atherosclerosis has been demonstrated 
experimentally. Similar immune complex deposition in coronary vessels 
of SLE patients may predispose to intimal thickening and atherosclerosis, 
thus increasing the frequency of myocardial infarction. Histologic 
findings at autopsy have  displayed both neutrophilic and lymphocytic 
infiltration, fibrinoid necrosis  and immune complex deposition. 
The etiology of the accelerated atherosclerosis in SLE in not  
known, but it has been linked to inflammation and endothelial 
dysfunction, a consequence of the inflammatory process. Flow-mediated 
dilatation is a non-invasive method of measurement  of endothelial 
dysfunction. It is based  on the change  in diameter of a conduit artery in 
response to increased flow, typically induced by a period of ischemia in 
the distal circulatory bed.  
The formation of immune complexes in patients with SLE  is 
strongly associated with acceleration of atherogenesis.The presence of 
autoantibodies to β2-glycoprotein-1 and  HDL-associated  protein and 
major antigen for anticardiolipin antibodies, is  strongly associated with  
inflammation in patients   with  SLE  as are autoantibodies to components 
of oxidized  LDL. In patients with SLE, immune complexes activate  
complement, which in turn acts on mast cells and basophilsto release 
vasoactive amines. These amines, which include   histamine and 5-
hydroxytryptamine, promote endothelial cell retraction and increased 
vascular permeability, induce   the expression of  endothelial adhesion 
molecules, and  attract polymorphs that subsequently infiltrate the area of  
damage Thrombin and inflammatory cytokines such as  interleukin-1, 
interleukin-6, and tumor necrosis factor–α  are also involved in this 
process. Following the trigger of adhesion molecule expression, 
preformed P-selectin is rapidly but transiently translocated to the 
endothelial surface, and within hours E-selectin is  also expressed . 
Subsequently, integrin molecules on  the leukocytes bind to 
immunoglobulin superfamily  receptors. For example, β2-integrins bind 
to intercellular   adhesion molecule–1, and monocyte α4β1 integrin binds 
to  vascular cell adhesion molecule–1 (VCAM-1).  These  molecules 
promote the capture and rolling of the leukocytes. Pro-oxidant molecules 
stimulate endothelial nuclear  factor κB (NF-κB), thereby promoting 
expression of  VCAM-1 and monocyte chemotactic protein–1 (MCP-1), 
and subsequently monocyte infiltration, by interaction with platelet-
endothelial cell adhesion molecule.  In diabetic  patients, advanced  
glycosylation   endproducts also  mediate  prolonged expression of    NF-
κB, and may be a mechanism  for the similar increased risk of 
cardiovascular   complications.28 Nitric oxide induces the endogenous  
inhibitor of NF-κB,  IκBα, which reduces expression of  both VCAM-1 
and MCP.  
Advances in medical therapy and a better understanding of 
systemic lupus erythematosus (SLE) have contributed to a dramatic 
improvement in the long-term survival of patients. However, despite the 
overall long-term improvement, coronary artery disease remains a major 
cause of  morbidity and mortality  with an incidence that is approximately 
nine-fold greater than would be expected for this population.  Following 
active lupus, coronary artery disease is the second most common cause of 
hospitalization for SLE patients.  Manzi et al. found that, when controlled 
for age and gender, women with SLE who are 35–44 years old have a 50-
times higher risk of myocardial infarction (MI).  Previous autopsy studies 
have observed that severe coronary artery disease is present in as many as 
40% of patients with SLE compared with only 2% of age-matched 
controls at the time of death.                                          
 
ANTIPHOSPHOLIPIDS ANTIBODY SYNDROME : 
The antiphospholipid syndrome (APS) is an acquired thrombotic 
disorder characterized by recurrent venous or arterial thrombosis or 
recurrent miscarriages, or both, associated with the presence in the serum 
of IgG or IgM anticardiolipin antibodies (aCL) and/or lupus anticoagulant 
(LAC). APS may occur as a primary disorder (PAPS) or associated with 
connective tissue diseases, mainly systemic lupus erthymatosus 
(secondary APS).Primary and secondary APS are both associated with a 
significant increase of cardiovascular risk.  
Atherosclerosis is an autoimmune/inflammatory disease associated 
with infectious, inflammatory, and autoimmune factors. Both humoral 
and cellular immune mechanisms have been proposed to participate in the 
onset and/or progression of atheromatous lesions. Heat-shock protein 
(hsp), oxidized low-density lipoprotein (LDL), and beta2-GPI have been 
reported to elicit humoral and cellular immune response in both 
experimental animals and humans. 
Antiphospholipid (antibody) syndrome  is a pathological condition 
that is also referred to as "Hughes syndrome." It originates from excess 
accumulation of blood clots by antiphospholipid  antibodies. The 
syndrome may occur as a  primary condition (primary APS) or along with  
the autoimmune disease, systemic lupus erthymatosus. SLE is a chronic 
disease that affects certain organs, blood vessels, or the  skin. The main 
signs of APS include blotchy  skin, migraine, memory loss, fatigue, deep 
vein   thrombosis, pulmonary embolism, and stroke. Primary APS may 
affect heart valves and present with such damage in 30% of patients. In  
pregnant women with APS, miscarriages may occur. 
 The recognition that a number of SLE manifestations have a  
thrombotic rather than  an  inflammatory basis can  be considered one of 
the most important recent contributions to rheumatology and 
immunology. The "anticardiolipin syndrome" described by   Graham 
Hughes in the 1980s, which was subsequently renamed antiphospholipid 
(Hughes) syndrome, appeared as a frequent condition in  patients with 
SLE but also was present in others without SLE or other autoimmune 
diseases. In  such cases it was termed a "primary" APS (PAPS). Almost 
20 years after its definition, APS has crossed over into many fields of 
medicine. However, the full spectrum of the  syndrome has yet  to be 
defined, though significant advances in the diagnosis and management of 
patients with APS  have been made. In addition, a consensus about  very 
important questions, such as the use of alternative tests for anticardiolipin 
(aCL) antibodies  and lupus anticoagulant (LA) assays, the  treatment of 
pregnancy failure, or the intensity of anticoagulant therapy, has not yet 
been  achieved.  
These autoantigens are expressed within atherosclerotic lesions. 
Immunization with the given autoantigens elicits an immune response 
that influences lesion progression. Atherosclerosis susceptibility can be 
transferred by autoantigen-sensitized lymphocytes from immunized 
animals. Patients with systemic lupus erthymatosus (SLE) and 
antiphospholipid syndrome (APS) have a high risk for atherosclerotic 
cardiovascular events. The traditional risk factors fail to fully account for 
accelerated atherosclerosis in SLE and APS. Immunological alterations, 
such as antibodies to oxidized LDL, antiphospholipid antibodies (aPL), 
antibodies to beta-2 Glycoprotein (anti-beta2-GPL), anti-prothrombin 
antibodies, may play a role in premature atherosclerosis in SLE and APS. 
Antiphospholipid antibodies(aPLs)  predict an increased  risk for MI, and 
their levels are increased in young survivors of MI.  ß2GP1 is a cofactor 
for antibody binding to cardiolipin, and recent studies indicate that many  
aCLs  recognize oxidized CL  (OxCL) and/or adducts of OxCL with 
ß2GP1. 
 The antiphospholipid antibody syndrome is characterized by both   
arterial and venous thrombosis and is common in SLE.  In the recent 
studies, lupus anticoagulant showed a significant association with IHD in  
SLE. In addition, both aCLs and anti-ß2GPI antibodies tended to be 
associated with arterial disease in  SLE. It is possible, therefore, that the 
increased risk of  IHD in SLE is to some extent caused by thrombosis.  
Thrombosis has been associated with the presence of a lupus 
anticoagulant(LAC) or antiphospholipid antibodies(APA) as part of a 
secondary antiphospholipid syndrome(APS). It has been noted that APA 
may promote cross-reactivity with anticardiolipin(aCL) binding to both 
the cardiolipin-protein complex and to oxidized low-density lipoprotein 
(LDL) cholesterol linking oxidation, inflammation, autoimmunity, 
atherosclerosis and thrombosis. However, it has also been suggested that 
the development of the antibody is an epiphenomenon as part of an 
immune reaction to vascular injury. The precise role of APA in coronary 
artery disease in SLE patients remains unclear. In addition, most studies 
have been retrospective and screened patients for APA after a thrombotic 
event had occurred. Thus, it has been debated whether the observed 
associations are causative or whether they are only markers for an 
inflammatory or immune response causing vascular injury. Interestingly, 
Vaarala it al. designed a prospective 5-year study in which it was found 
that the APA levels were significantly higher in patients with MI than in 
age- and gender- matched controls, even after adjusting for conventional 
risk factors.  
Recently many authors have been trying to find a correlation 
between the presence of aPL and thrombosis of coronary arteries, in the 
absence or limited arteriosclerotic changes. Prospective studies prove the 
close relationship between the presence of  aPL and development of AMI 
and reinfarction. The frequency of AMI in APS varies, according to 
literature data. Some authors find out a connection between ACA and 
AMI in 21% of cases. 
It is assumed that aPLs are a significant risk factor for AMI in 
selected patients. According to Adler et al, aPL precede the infarction, 
rather than follow it. The results he obtained regarding the frequency of 
APS in AMI (38%) are a little higher, as compared with authors cited 
above. This could be attributable to proper initial selection of patients, 
suspected for APS. The increased values of ACA, ß2GP1 antibodies and 
CD31 registered in patients with AMI correlate well with the 
development of arterial thrombosis, and some disputable pathogenic 
mechanisms of arising of hyper coagulation in patients with APS. 
According to Galli et al, the presence of ACA and ß2GP1 antibodies in 
patients with systemic lupus erthymatosus is connected with a risk for 
development of arterial thrombosis. Many authors consider ß2GP1, which 
is the main co-factor of binding between ACA and cardiolipin, as one of 
the key structures. On the other hand, a direct formation of antibodies 
against ß2GP1 is also observed in APS. The importance of ß2GP1 is 
connected with its functions of a natural coagulant, namely the blocking 
of the contact system of coagulation, inhibition of adenosine diphosphate-
depending aggregation and the synthesis of factor Xa from the activating 
platelets, as well as the inhibition of prothrombinase activity of 
inactivated platelets.  Recently, there are reports that in patients with 
secondary APS, antibodies against ß2GP1 can be used as a target for 
immune mediated atherogenesis. Anti- ß2GP1 antibodies can trigger 
other mechanisms - to activate the endothelium cells and activate 
adhesion molecules such as ICAM-1, VCAM-1, and E-selectin. 
The arising of thrombosis in APS is also associated with increased 
activity of thrombotic endothelium adhesion molecules CD31. CD31 is 
expressed on platelets, neutrophils, monocytes and endothelium cells, and 
it plays a significant role in their interaction.  Apart from the signal 
function it has, CD31 also activates the ß-3 subgroup of integrins, which 
in turn play a crucial role in the adhesion of cells. It is not by chance that 
the flowcytometric investigation of the expression of CD31 on the 
circulating platelets is recommended as an important method for 
investigating thrombotic conditions. The  increased expression of the 
marker in the chronic stage of myocardial infarction  correlate well with 
the observation in cases of APS following thrombosis, and they prove the 
significance of CD31 in the pathogenesis of APS. 
In conclusion, it is  considered  that number of studies   carried out 
confirm the proposition that aPL play an important role in the 
pathogenesis of acute coronary incidences. The timely diagnosis of APS 
could improve the prognosis, prevention and treatment of patients in this 
risk group. 
                                      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and 
methods
MATERIALS 
SUBJECTS : 
Patients who are all positive to Rheumatoid factor (RF) attending  
RHEUMATOLOGY CLINIC, COIMBATORE  MEDICAL COLLEGE  
HOSPITAL between  September 2007—September 2009. 
PERIOD  OF STUDY : 
September 2007— September 2009 
DESIGN  OF STUDY: 
Cross sectional observational study  
ELIGIBILITY CRITERIA: 
All patients with  RHEUMATOID ARTHRITIS (RF positive by 
ELISA)          
 
EXCLUSION CRITERIA: 
                    1. Chronic infection 
                    2. Elderly patients (>60 years)  
                    3. Patients with thyroid abnormality 
    
 
 
 
INCLUSION CRITERIA: 
         1. Hypertension 
         2. Obesity 
         3. Diabetes mellitus 
         4. H/O smoking, 
         5. H/o IHD 
         6. Family h/o IHD 
 
 
 
    
 
 
                      
 
                               
 
 
                                    
METHODOLOGY 
 
One hundred patients with rheumatoid arthritis and with 
RHEUMATOID FACTOR positive   attending RHEUMATOLOGY 
CLINIC, COIMBATORE MEDICAL COLLEGE HOSPITAL  during 
the study period were evaluated for  IHD  by ECG and ECHO. 
Those  who are  included  in  the  study were evaluated for 
traditional  risk factors like  h/o Diabetes, smoking ( in the past / present), 
family h/o IHD and they were clinically examined for hypertension, body 
mass index for Obesity and  features of RA. Patient with  BP >140/90 
mmHg were  considered as hypertensive in this study. Fasting blood for 
sugar and lipid profile were measured. They were also evaluated  for RF 
positivity, high or low titres  by ELISA. A resting 12 lead ECG  was 
carried out for features of IHD. The following changes in the ECG were 
taken as marker of ischemia                                      
1) The combination of ST elevation  in atleast two contagious 
leads and reciprocal ST depression in atleast two contagious 
leads.  
2) Inversion of T with ST still being elevated. 
3) Presence of pathological Q waves. 
 
STATISTICAL ANALYSIS:                                    
Statistical analysis was done using standard formulae  SPSS 
(Statistical Package for social sciences) in windows Dos version. Base 
line data like age, gender, RF, Traditional risk factors were collected. 
Patients were categorized  on their RF positive with or without traditional 
risk factors and Ischemic changes. 
 The significance of  association between the factors  was collected 
using PEARSON  CHI-SQUARE TEST and YATES Corrected                 
CHI-SQUARE TEST. P<0.05 was taken as significant.     
 
CRITERIA CONSIDERED IN THE STUDY 
S.NO PARAMETERS VALUES 
 
1 
 
2 
 
3 
 
4 
 
 
 
 
 
 
 
 
 
5 
 
 
 
 
 
 
 
 
       Obesity ( BMI ) 
 
       Hypertension: 
 
       Diabetes -Fasting blood sugar 
 
 Abnormal Lipid profiles; 
 
            VLDL: 
 
             LDL: 
 
             HDL: 
     
             TGL: 
 
Rheumatoid factor; 
     (BY ELISA technique) 
                  
           HIGH TITRE: 
 
 LOW TITIRE: 
 
>23 
 
>140/90mmhg 
 
> 110 mg/dl              
 
 
 
       >100 mg/dl 
 
       >100mg/dl 
 
       <40mg/dl  
 
       >160mg/dl            
 
 
 
        
          >320 IU/ml 
        
          <320 IU/ml 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION & 
RESULTS
OBSERVATIONS AND RESULTS 
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TOTAL NUMBERS OF PATIENTS(n) 
 
                                                 FEMALE 
 
                                                 MALE 
 
AGE 
 
                                                 ≤40YEARS 
 
                                                  41-60YEARS 
 
ECG-ISCHEMIC CHANGES 
                                                    TOTAL 
 
               A. WITH TRADITIONAL FACTORS 
 
                                                        
                                                         MALE 
 
                                                        FEMALE 
 
 
               B. ONLY RF POSITIVE 
 
                                                        MALE 
 
                                                        FEMALE 
 
                                                     
                                           HIGH TITIRE RF 
                                                      
                                           LOW TITIRE RF 
 
 
 
 
100 
 
70 
 
30 
 
 
 
44 
 
56 
 
 
20 
 
14 
 
 
10 
 
4 
 
 
6 
 
5 
 
1 
 
 
4 
 
2 
 
 
 
 
AGE DISTRIBUTION: 
           Of  the  hundred patients with RF positivity , there were 70 
females and 30 males, age distribution of those included in the study are 
showed in table no:1 
 
TABLE NO-1 AGE DISTRIBUTION IN RELATION TO SEX 
AGE MALE FEMALE 
21-30 4 13 
31-40 5 22 
41-50 10 19 
51-60 11 16 
 
 
CHART NO-1 AGE DISTRIBUTION IN RELATION TO SEX 
0
5
10
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 TABLE -2:  ISCHEMIC CHANGES IN THE TOTAL 
POPULATION UNDER STUDY IN PERCENTAGE: 
ECG CHANGES FREQUENCY  PERCENTAGE 
PRESENT 20(100) 20% 
ABSENT 80(100) 80% 
 
 
CHART-2 : ISCHEMIC CHANGES IN RF POSITIVE PATIENTS 
 
 
 
80
20
TOTAL NUMBER OF PATIENTS-100 
NO ECG CHANGES
ECG CHANGES
TABLE -3: AGE AND SEX DISTRIBUTION IN RELATION TO 
ISCHEMIC CHANGES OF RF WITH TRADITIONAL RISK 
FACTORS 
AGE & SEX DISTRIBUTION OF ISCHEMIC CHANGES 
AGE MALE FEMALE  
21-30 2 0  
31-40 2 1  
41-50 5 1  
51-60 6 3  
 
TABLE -4: AGE  DISTRIBUTION OF ISCHEMIC CHANGES IN 
RELATION TO RF INCLUDING TRADITIONAL RISK 
FACTORS: 
                                                 χ2=1.77 
 P=0.18  NOT SIGNIFICANT 
 
On comparing below 40age : 40-60age  1:1.77  ratio by chi square 
test, the P value is 0.18 which is > 0.05.so,it is not significant. The 
ECG-ISCHEMIC CHANGES 
AGE NUMBERS PERCETAGE 
 <40 yrs 5(44) 25% 
 41-60yrs 15(56)                      75% 
association between age distribution in RF positive patients is not 
significant. 
CHART-3: AGE DISTRIBUTION OF ISCHEMIC CHANGES IN 
RELATION TO RF POSITIVITY WITH TRADITIONAL RISK 
FACTORS: 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
<40YEARS 40-60YEARS
NO ISCHEMIC CHANGES
ISCHEMIC CHANGES
 
 
 
TABLE-5: SEX DISTRIBUTION IN RELATION TO ISCHEMIC 
CHANGES  DUE  TO  RF WITH TRADITIONAL RISK FACTORS 
 
 
ECG-ISCHEMIC CHANGES 
SEX       PRESENT   ABSENT 
MALE 10(12) 2(12) 
FEMALE 4(18) 14(18) 
                                   χ2= 8.49 / P=0.0035 (SIGNIFICANT) 
The study shows that 83.33%  of males and 28.57% of females 
with  RF positive with traditional risk factors  had  ischemic changes . On 
comparing the male, female ratio  (2.2:1) by chi square test, the P value is  
0.0035. This indicating that males with RF and traditional risk  factors  
have greater risk of  IHD compared to females.                       
CHART-4:  SEX  DISTRIBUTION  OF  ISCHEMIC CHANGES IN 
RELATION TO RF INCLUDING TRADITIONAL RISK 
FACTORS: 
0
10
20
30
40
50
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ECG CHANGES NO ECG CHANGES
MALE
FEMALE
 
In the present study, a total of 20 patients had ischemic changes in 
the ECG. Among the patients, there were 15 males and 5 females. The 
proportion of patients with ischemic changes in ECG were higher for 
males accounting for 50% of the male population in the study. 
TABLE 6: AGE AND SEX DISTRIBUTION IN RELATION TO 
ISCHEMIC CHANGES DUE TO RF WITHOUT TRADITIONAL 
RISK FACTORS: 
RF WITHOUT TRADITIONAL RISK 
FACTORS-   ECG CHANGES 
AGE 
DISTRIBUTION 
MALE  FEMALE TOTAL 
21-30 1(3) 0(12) 1(15) 
31-40 1(2) 0(20) 1(22) 
41-50 1(6) 1(13) 2(19) 
51-60 2(7) 0(7) 2(14) 
 
 
A total of 6 patients had ischemic changes in the ECG in the study 
population without having any traditional risk factors. Among the 6 
patients, there were 5 males and only one female.  
 
TABLE-7: SEX DISTRIBUTION OF ISCHEMIC CHANGES IN 
 
RELATION TO RF POSITIVITY WITH VARYING TITRES: 
 
 
ISCHEMIC CHANGES IN ECG(N=20) 
MALE(15) FEMALE(5) 
RF-HIGH TITRE 
10 (50%) 
RF-LOW TITRE 
5  (25%) 
RF-HIGH TITRE 
2  (10%) 
RF-LOW TITRE 
3  (15%) 
 
 
CHART-5: SEX DISTRIBUTION OF  ISCHEMIC CHANGES IN 
 
RELATION TO RF POSITIVITY WITH VARYING TITRES: 
0
1
2
3
4
5
6
7
8
9
10
MALE FEMALE
HIGH TITRE
LOW TITRE
 
 
In the present study there were 20 patients who had  RF positivity 
with Ischemic changes in ECG. 15 were males and 5 were females. Of 
these 10 males and 2 females had high titre of RF with ischemic changes. 
Thus the majority of patients with high titre of  RF along with ischemic 
changes are males.                         
 
TABLE- 8:  SEX DISTRIBUTION IN  RELATION TO ISCHEMIC 
CHANGES IN LONE RF POSITIVE AND TITRES 
ECG ISCHEMIC CHANGES 
PRESENT ABSENT 
SEX RHEUMATOID 
FACTOR 
NUMBER PERCENT NUMBER PERCENT 
HIGH TITRE 4 100% _ _ 
MALE 
LOW TITRE 1 7.14% 13 92.86% 
HIGH TITRE 0 _ 18 100% 
FEMALE 
LOW TITRE 1 3% 33 97% 
          
Subjects with ischemic changes with RF positivity alone without 
the presence of traditional risk factors were tabulated above with sexual 
differentiation and also with respect to varying titres of  RF. 
 
TABLE- 9:  SEX DISTRIBUTION IN  RELATION TO ISCHEMIC 
CHANGES IN LONE RF POSITIVE AND TITRES: 
ISCHEMIC CHANGES IN ECG(N=6) 
MALE(5) FEMALE(1) 
RF-HIGH TITRE 
4 (80%) 
RF-LOW TITRE 
1  (20%) 
RF-HIGH TITRE 
0 
RF-LOW TITRE 
1 
          
 
CHART-6 :  ISCHEMIC CHANGES IN ECG IN RELATION TO 
LONE RF POSITIVE AND TITRES                      
14
4
2
WITH TRADITIONL RISK 
FACTORS
RF-HIGH TITRE
RF-LOW TITRE
 
In the present study Lone RF without traditional risk factors was 
seen in only 5 male patients, with only one female patient .Of the 5 male 
patients 4 had high titre RF (>320). Considering the association of 
traditional risk factors a an additional risk factor with RF positivity, 14 
had ischemic changes.  
 
In men                     
            5/30 ==16.66%                    
                       CONFIDENCE INTERVEL= 4 – 28  
                   χ2YATES CORRECTED    P=0.01  (significant) 
In study population 
                   5/100== 5% 
                 CONFIDENCE INTERVEL= is 1.7-5.4. 
                 χ2YATES CORRECTED    P=0.01  (significan)                                                            
 
TABLE-10 :  ISCHEMIC CHANGES IN RELATION TO RF WITH 
AND WITHOUT TRADITIONAL RISK FACTORS IN 
PERCENTAGE: 
ECG ISCHEMIC CHANGES 
POSITIVE NEGATIVE 
RF WITH 
TRADITIONAL 
RISK 
FACTORS NUMBER PERCENTAGE NUMBER PERCENTAGE
Present 14 50% 14 50% 
Absent 6 8.33% 66 91.66% 
 χ2= 19 .35;  P=0.00001   (significant)  
Subjects with ischemic changes in RF positive with traditional risk 
factors are 50 % without traditional risk factors are 8.33 % . On 
comparing  these values by  chi square test , P value is 0.0001which is 
statistically significant.  
 
CHART-7:  ISCHEMIC CHANGES IN RELATION TO RF WITH 
AND WITHOUT TRADITIONAL RISK FACTORS :  
80
14 6
NO ECG CHANGES
ECG CHANGES ASSOCIATED 
WITH TRADITONAL RISK 
FACTOR
ECG CHANGES ASSOCIATED 
WITH ONLY RF
 
 
                                                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Discussion
DISCUSSION 
In the study population, most of  the  RF positive patients clustered  
between 30-50 years. Dividing the study population with  ischemic 
changes by ECG, by  age,  25%  were   below 40 years and 75% were 
above  40 years. All of the above patients had RF positivity along  with 
traditional risk factors  and  ischemic changes in the ECG. 
In this  study  30% were males and  70% were females. The M:F 
ratio was   1 : 2.33.   20  patients had   ischemic changes in ECG 
constituting 15 males (50%) and 5 females (7.14%)patients of the total 
study population. This is concordant with  Edwards  C J et al1 where  the  
M:F ratio was 1 : 1.02 . Comparatively females were more common in 
present study population. This is  because the patients selected  were  
suffering from RA which is more common in females. Considering the 
ischemic changes, males were affected  more than females though more 
number of  female patients were  included in the study. This is also  
similar to Edwards  C J et al1                              
Evaluating the 20% (n=20) who were RF  positive  with ischemic 
changes, 14 patients  had traditional risk factors(70%).The other 6 
patients had only RF positivity without any other traditional risk factor. 
Among these 5 patients were males and there was only one female. This 
indicates an association  of  RF and IHD a strong possibility especially in 
males.  
Among the 10male patients who had RF positivity with traditional 
risk factors  and ischemic changes, 6 patients had  high titre of RF and 4 
patients had low titre. Percentage wise  42.85%  and  28.57% were having  
high and low titres of  RF along with traditional risk factors  causing 
IHD. This is concordant  with both Edwards  C J et al1, Kenneth J 
Warrington  et al4. 
Among the 4 female patients  who had RF positivity with 
traditional risk factors , 2 patients  had ischemic changes with high titre of 
RF  making up  12.5%. 2 patients had ischemic changes with low titre RF 
and traditional risk factors  forming 12.5% This is disconcordant  with  
both Edwards C J et al1, Kenneth J Warrington  et al4. 
By these data this study shows that, RF with traditional risk factors  
have increased incidence of  ischemic changes in males than females 
especially with high titre RF.         
In this study  only 6 patients had  RF positivity without traditional 
risk factors  along with ischemic changes and among them 5 were males 
and there was only one female. This is  27.7% of  the total RF positive 
males without traditional risk factors  in study population and 16.66%  
total male patients in the study population. Only one female patient had 
ischemic changes in ECG with lone RF without traditional risk factor. 
This is 1.9% of the total RF positive females without traditional risk 
factors and 1.4% of the total female patients in the study. This study is in 
concordance with Edwards  C J et al1  
The  long term Herfordshire  Cohort  study reported by  Sydall H E 
et al5 had similar results. RF positive male patients  without  traditional 
risk factors are vulnerable to IHD. Females with traditional risk factors 
did not have IHD – this is discordant with this study. Our study indicated 
that IHD may be associated  with  RF and traditional risk factors in 
females which is as in the study of  Sydall H E et al5 
Of these 5 male patients, 4 patients had  high titre of  RF positivity  
which is 80% and one patient had  low titre of  RF which is 20% .This  
suggested that a high titre of RF may have  an increased incidence of 
IHD. This  concurs with  the earlier study by  Edwards  C J et al1  and del  
Puente A et al3              
In this study, Autoantibody RF which is risk factor for IHD in men 
is 16.66% (5 out of 30); confidence interval(CI)  is  5-28  and  5% (5 out 
of 100)  study population;  This   goes  with many  other similar  studies 
from various parts  of the world. 
Most of the of  the studies state the  prevalence  to be  between  4-
28%. Edwards  C J et al1- 11.6%( in men), Kenneth J Warrington1 et al4 -
1.97% (in general population). 
From the observation and analysis of study, it is assumed that there 
is an association between high titre of RF and IHD. This association was 
significantly more in  male patients.                               
This study has a number of  potential limitations. The study is 
conducted with the maximum available resources in the hospital. The 
most important is the fact that this is a cross-sectional study  and  will  
need confirmation by  a longitudinal cohort study.                                     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
conclusion
CONCLUSIONS 
¾ RF  can be considered  as one of the risk factor for Ischemic 
heart disease in males. 
¾ High titre RF  alone can  further increase the incidence of IHD. 
¾ RF in association with other traditional risk factors increase the 
prevalence of IHD. 
¾ Though more female patients have positive RF ,they are not 
vulnerable to IHD. 
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annexures
PROFORMA 
Name: 
Age: 
Sex: 
OP No. 
Address: 
Presenting Complaints:- 
H/o HT  
H/o Diabetes Mellitus 
H/o IHD 
H/o Smoking  
Family H/o IHD 
Rhematalogical H/O 
EXAMINATION: 
           Pulse:                             
           BP: 
          CVS: 
           RS: 
           P/A: 
           CNS: 
 
INVESTIGATIONS:       
             BLOOD GLUCOSE: 
                      Fasting 
                      Post prandial  
             S.LIPID PROFILE:                        
                     TOTAL CHOLESTROL 
                     VLDL 
                     LDL 
                     HDL 
                     TGL     
             BODY MASS INDEX : 
             RHEUMATOID FACTOR: 
                    High titre 
                    Low titre 
            ELECTROCARDIOGRAM: 
            ECHO : 
 
 
 
 
 
 
ABBREVIATIONS 
 
ACL :  ANTI CARDIOLIPIN ANTIBODIES 
AMI :  ACUTE MYOCARDIAL INFARCTION 
APS : ANTI PHOSPHOLIPID SYNDROME 
BMI :  BODY MASS INDEX 
CCP :  CITRULINATED CYCLIC POLYPEPTIDE 
CHD :  CORONARY HEART DISEASE 
CRP :  C-REACTIVE PROTEIN 
CVD :  CARDIO VASCULAR DISEASE 
ESR :  ERTHROCYTE SEDIMENTATION RATE 
HDL :  HIGH DENSITY LIPOPROTEIN 
IHD :  ISCHEMIC HEART DISEASE 
LDL :  LOW DENSITY LIPOPROTEIN 
RA :  RHEUMATOID ARTHRITIS 
RF :  RHEUMATOID FACTOR 
SLE :  SYSTEMIC LUPUS ERTHYMATOSUS 
TGL :  TRIGLYCERIDE 
VLDL :  VERY LOW DENSITY LIPOPROTEIN 
MASTER CHART 
TRADITIONAL RISK FACTORS 
SL NO AGE SEX OP NO RA RF 
SMOKING       DM       HT OBESITY DYSLIPIDEMIA FAMILY H/O IHD 
ECG CHANGES ECHO CHANGES 
1 36 F 3079624 YES HT NO NO NO NO NO NO NO NO 
2 39 M 750108 YES LT NO NO NO NO NO NO NO NO 
3 50 F 586833 YES LT NO NO NO NO NO NO NO NO 
4 45 F 550576 YES HT NO YES YES NO NO YES YES YES 
5 44 F 527540 YES HT NO NO NO NO NO NO NO NO 
6 54 F 521345 YES LT NO NO YES NO NO NO NO NO 
7 50 F 484537 YES LT NO NO NO NO NO NO NO NO 
8 54 F 463799 YES LT NO YES YES NO NO NO NO NO 
9 51 M 460695 YES LT NO NO NO NO NO NO NO NO 
10 59 M 438081 YES LT NO YES YES NO NO NO YES YES 
11 37 M 429440 YES HT NO NO NO NO NO NO YES YES 
12 36 F 428996 YES HT NO NO NO NO NO NO NO NO 
13 40 F 426348 YES LT NO NO NO NO NO NO NO NO 
14 40 F 426348 YES LT NO YES NO NO NO YES NO NO 
15 50 M 417697 YES LT NO NO NO NO NO NO NO NO 
16 30 M 413188 YES HT NO NO NO NO NO NO YES YES 
17 39 F 402532 YES LT NO NO NO NO NO NO NO NO 
18 23 F 367392 YES LT NO NO YES NO NO NO NO NO 
19 44 F 353178 YES LT NO YES NO NO NO NO NO NO 
20 60 M 323451 YES LT NO NO NO NO NO NO NO NO 
21 57 M 323003 YES LT NO NO NO NO NO NO YES YES 
22 36 F 322646 YES LT NO NO NO NO NO NO NO NO 
23 36 F 322646 YES HT NO NO NO NO NO NO NO NO 
24 42 F 322568 YES HT NO NO NO NO NO NO NO NO 
25 27 F 322487 YES LT NO NO NO NO NO NO NO NO 
 TRADITIONAL RISK FACTORS SL 
NO AGE  SEX OP NO RA RF 
SMOKING       DM       HT OBESITY DYSLIPIDEMIA FAMILY H/O IHD 
ECG 
CHANGES 
ECHO 
CHANGES 
26 27 F 322487 YES HT NO NO NO NO NO NO NO NO 
27 33 F 322255 YES LT NO NO NO NO NO NO NO NO 
28 60 F 321701 YES LT NO NO NO NO NO NO NO NO 
29 32 M 320820 YES HT NO NO YES YES NO YES YES YES 
30 45 F 319398 YES HT NO NO NO NO NO NO NO NO 
31 60 F 317874 YES LT NO NO YES NO NO NO NO NO 
32 22 M 313872 YES LT NO NO NO NO NO NO NO NO 
33 47 M 311345 YES HT NO YES NO YES YES NO YES YES 
34 49 F 311345 YES LT NO YES NO NO NO NO NO NO 
35 52 F 311345 YES LT NO YES YES NO NO NO NO NO 
36 38 F 304966 YES LT NO NO NO NO NO NO YES YES 
37 42 M 304302 YES LT NO NO NO NO NO NO NO NO 
38 47 M 297630 YES HT YES NO YES YES NO NO YES YES 
39 59 M 293602 YES LT NO NO NO NO NO NO NO NO 
40 47 F 293378 YES HT NO NO NO NO NO NO NO NO 
41 30 F 291110 YES LT NO NO NO NO NO NO NO NO 
42 51 F 285012 YES LT NO YES NO NO NO NO NO NO 
43 54 M 281817 YES LT NO NO NO NO NO NO NO NO 
44 57 F 278180 YES HT NO NO NO NO NO NO NO NO 
45 56 F 256410 YES LT NO YES NO YES YES NO YES YES 
46 25 F 251880 YES LT NO NO NO NO NO NO NO NO 
47 38 M 228153 YES LT YES NO YES NO NO NO YES YES 
48 40 F 225554 YES LT NO NO NO NO NO NO NO NO 
49 60 F 218078 YES HT NO NO NO NO NO NO NO NO 
50 60 F 218078 YES HT NO NO NO NO NO NO NO NO 
 
 TRADITIONAL RISK FACTORS SL 
NO AGE  SEX OP NO RA RF SMOKING       DM       HT OBESITY DYSLIPIDEMIA FAMILY H/O IHD 
ECG 
CHANGES 
ECHO 
CHANGES 
51 41 M 210599 YES LT NO NO NO NO NO NO NO NO 
52 29 F 198890 YES LT NO NO NO NO NO NO NO NO 
53 60 F 196067 YES LT NO YES YES YES NO NO YES YES 
54 52 M 176202 YES HT NO YES NO NO NO NO NO NO 
55 49 F 167365 YES LT NO NO YES NO NO NO NO NO 
56 52 F 150308 YES LT NO NO YES NO YES NO NO NO 
57 23 M 147204 YES LT NO NO NO NO NO NO NO NO 
58 36 F 141846 YES HT NO NO NO NO NO NO NO NO 
59 29 F 140283 YES LT NO NO NO NO NO NO NO NO 
60 29 F 134536 YES HT NO NO NO NO NO NO NO NO 
61 35 F 132368 YES HT NO NO NO NO NO NO NO NO 
62 35 F 132368 YES LT NO NO NO NO NO NO NO NO 
63 36 F 116051 YES LT NO NO NO NO NO NO NO NO 
64 47 M 106804 YES HT NO NO YES NO NO NO YES YES 
65 50 F 103918 YES HT NO NO NO NO NO NO NO NO 
66 30 F 96287 YES LT NO NO NO NO NO NO NO NO 
67 26 F 95245 YES LT NO NO NO NO NO NO NO NO 
68 30 F 86694 YES LT NO NO NO NO NO NO NO NO 
69 49 F 68551 YES LT NO NO NO NO NO NO NO NO 
70 47 M 65949 YES HT NO YES NO YES NO YES YES YES 
71 48 F 59866 YES HT NO NO YES YES NO NO YES YES 
72 48 F 59866 YES LT NO YES NO NO NO NO NO NO 
73 48 F 54196 YES LT NO NO NO NO NO NO NO NO 
74 60 F 39021 YES LT NO NO NO NO NO NO NO NO 
75 60 M 32594 YES LT YES NO YES NO NO NO YES YES 
 
 TRADITIONAL RISK FACTORS SL NO AGE  SEX OP NO RA RF SMOKING       DM       HT OBESITY DYSLIPIDEMIA FAMILY H/O IHD 
ECG 
CHANGES 
ECHO 
CHANGES 
76 24 M 31734 YES LT NO NO NO NO NO NO NO NO 
77 30 F 29529 YES LT NO NO NO NO NO NO NO NO 
78 43 M 29328 YES HT NO NO NO NO NO NO YES YES 
79 49 F 29224 YES LT NO NO NO NO NO NO NO NO 
80 57 M 25869 YES LT NO YES YES NO NO NO YES YES 
81 58 M 25310 YES LT NO NO NO NO NO NO NO NO 
82 40 F 24420 YES LT NO NO NO NO NO NO NO NO 
83 39 F 24142 YES LT NO YES NO NO NO NO NO NO 
84 41 M 23897 YES LT NO NO NO NO NO NO NO NO 
85 39 F 21389 YES LT NO NO NO NO NO NO NO NO 
86 41 F 19242 YES LT NO NO NO NO NO NO NO NO 
87 32 F 18293 YES LT NO NO NO NO NO NO NO NO 
88 45 F 16539 YES HT NO NO NO NO NO NO NO NO 
89 51 F 16510 YES LT NO NO NO NO NO NO NO NO 
90 50 F 15237 YES HT NO NO NO NO NO NO NO NO 
91 21 F 14261 YES LT NO NO NO NO NO NO NO NO 
92 60 F 10984 YES LT NO YES YES NO NO NO NO NO 
93 36 F 9081 YES LT NO NO NO NO NO NO NO NO 
94 55 M 7429 YES HT NO NO NO NO NO NO YES YES 
95 35 F 7423 YES LT NO NO NO NO NO NO NO NO 
96 33 F 2549 YES LT NO NO NO NO NO NO NO NO 
97 39 F 2338 YES LT NO NO NO NO NO NO NO NO 
98 41 M 1642 YES HT NO NO NO NO NO YES NO NO 
99 55 F 1540 YES HT NO NO NO NO NO NO NO NO 
100 33 M 1416 YES HT NO YES YES NO NO NO YES YES 
 
